A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
for Non Small Cell Lung Cancer
49 locations incl. Little Rock
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06312137·Phase 3·Recruiting